After the introduction of monovalent rotavirus vaccine (RV1) in Mexico in 2006-2007, diarrhea mortality and morbidity declined substantially among Mexican children under 5 years of age. In January 2010, surveillance identified the emergence of a novel G9P [4] rotavirus strain nationwide. We conducted a case-control study to assess the field effectiveness of RV1 against severe rotavirus gastroenteritis caused by this unusual strain and to determine whether the G9P [4] emergence was related to vaccine failure or failure to vaccinate. RV1 was 94% effective (95% confidence interval, 16%-100%) against G9P [4] rotavirus-related hospitalization, indicating that its emergence was likely unrelated to vaccine pressure.
After the introduction of routine vaccination of infants in Mexico in 2006-2007 with a live-attenuated, monovalent rotavirus vaccine (RV1), diarrhea mortality and morbidity declined substantially among Mexican children ,5 years of age. Compared with prevaccine years, all-cause diarrhea-related mortality decreased by 41% [1] and diarrhea-related hospitalizations by 52% [2] among infants 0-11 months of age, at a time when 2-dose RV1 coverage was greater than 70% for this age group.
The existing evidence suggests that RV1, which is given orally at 2 and 4 months of age in Mexico, provides good homotypic and heterotypic protection against common circulating rotavirus strains [3] [4] [5] . However, because more than 60 G and P rotavirus serotype combinations have been found in humans, there is concern that vaccination pressure may cause emergence of previously uncommon, heterotypic rotavirus strains. Between January 2010 and March 2010, Mexican health authorities noted an increase in the number of reported suspected rotavirus gastroenteritis cases compared with the same time period during previous years. At the same time, the national passive diarrhea surveillance system identified G9P [4] rotavirus strains in 23 of 32 states (including the Federal District) [6, 7] . G9P [4] rotavirus is likely a naturally occurring reassortant between 2 common human rotavirus strains, given the predominance of G1P [8] , G2P [4] , G3P [8] , G4P [8] , and G9P [8] strains globally [8] . Although the G9P [4] rotavirus strain has been identified in various countries, its occurrence is not common [9] [10] [11] [12] . In Mexico, G1P [8] , G3P [8] , G2, and G4 have been the prevalent strains in previous reports [13, 14] . Although the detection of some unusual strains (eg, G1P [4] ) have infrequently been reported in Mexico [15] , detection of the G9P [4] strain has not. Given the rarity in Mexico of the G9P [4] strain, which is fully heterotypic to the G1P [8] strain in RV1, the identification of this strain prompted concern that less than complete cross-protection against the G9P [4] strain by RV1 led to immunologic selection of this strain.
The occurrence of G9P [4] rotavirus in Mexico provided a valuable opportunity to assess the field effectiveness of RV1 against severe rotavirus gastroenteritis caused by this unusual strain, which did not circulate widely during prelicensure trials of RV1, and to determine whether the G9P [4] emergence was related to vaccine failure or failure to vaccinate.
METHODS
A case-control assessment of RV1 effectiveness against hospitalization related to G9P [4] rotavirus gastroenteritis was conducted between March 2010 and May 2010 in 3 municipalities of the state of Chiapas (Tapachula, Villaflores, and Huixtla), in which the majority of suspected rotavirus gastroenteritis cases occurred during the outbreak period. Informed consent was collected from all participants. Case patients were identified from patients hospitalized with acute rotavirus gastroenteritis and defined as children between 15 days and exactly 2 years of age with laboratory-confirmed G9P [4] rotavirus gastroenteritis. Case patients who were age-eligible to have been fully vaccinated with a 2-dose series of RV1 (ie, were $5 months of age) were matched with community controls who were age-eligible to have been fully vaccinated, who were born within 3 months of the case patient's date of birth, and who resided in the same municipality as the case patient. Case patients who were too young to have been fully vaccinated were matched with community controls who were born within 1 month of the case patient's date of birth and who resided in the same municipality as the case patient. Information on demographics, socioeconomic indicators (ie, maternal education, motorized vehicle ownership, and the presence of electricity, a telephone, or a computer at home), history of breastfeeding, medical history, and symptoms and disease severity were obtained through parental interview. Vaccination history was confirmed through vaccination card review at the time of the interview.
Stool specimens of patients hospitalized with suspected rotavirus gastroenteritis were tested for the presence of rotavirus using rotaphoresis at the state laboratory. Stool specimens underwent viral RNA extraction and then polyacrylamide gel electrophoresis for rotavirus identification. Of the specimens that were rotavirus positive, 10% were randomly selected for strain characterization by reverse transcription-polymerase chain reaction (RT-PCR) and nucleotide sequencing methods at the Epidemiological Diagnostics and Reference Institute. Because strain typing data were not available for all case patients, the analysis was restricted to case patients hospitalized with confirmed G9P [4] rotavirus gastroenteritis and their matched controls.
Case patients and controls were considered vaccinated if the vaccination date was $14 days prior to the case patient's date of Computer in home 1 (7) 2 (7) 1.00
NOTE. Values are no. (%) unless stated otherwise. a Data were missing for the following variables: history of breastfeeding (1 case), history of premature birth (4 cases, 9 controls), maternal education (1 control), number of children in household (2 controls), number of people in household (2 controls), electricity in home (2 controls), telephone in home (1 control), computer in home (1 control).
12 months (range, 3-18 months) and 13 months (range, 3-19 months), respectively. Twenty-one percent of case patients had received a complete 2-dose series of RV1 versus 48% of controls (Table 2 ; P 5 .04). For children 6 months and older, 25% of case patients had received a 2-dose series of RV1 versus 50% of controls. Effectiveness of a complete 2-dose series of RV1 against laboratory-confirmed G9P [4] rotavirus infection resulting in hospital admission was 94% (95% confidence interval, 16-100; P 5 .03).
DISCUSSION
Our analysis found that RV1 protects against severe rotavirus gastroenteritis caused by strains fully heterotypic from the vaccine strain. The VE against G9P [4] gastroenteritis was similar to the efficacy against homotypic strains seen in the prelicensure clinical trial from Latin America and to the effectiveness seen against another fully heterotypic strain, G2P [4] , in postlicensure case-control studies from Brazil [3, 4] . Moreover, because the performance of rotavirus vaccines has been lower in the poorest settings compared with high-income settings, it was reassuring that RV1 provided good efficacy in Chiapas, the poorest state in Mexico, with an annual GDP similar to that of a developing country.
This evaluation in Chiapas was undertaken because routine diarrhea surveillance identified G9P [4] rotavirus strains in 23 of 32 states across Mexico [6] . Although it was not feasible to conduct a wide-scale evaluation in different regions, because of the gradient in VE by socioeconomic status with lower VE in developing settings, we suspect that the efficacy against G9P [4] is likely similar in other more developed settings of Mexico compared with the poor setting of Chiapas. Thus, failure to vaccinate, rather than failure of vaccine performance or vaccination pressure on rotavirus strain ecology, likely contributed to the G9P [4] -related rotavirus hospitalizations in Mexico during 2010.
This evaluation has some limitations primarily relating to the observational nature of the evaluation and the small sample size. Vaccination data were card-confirmed, but erroneous recording of vaccination dates could have led to some misclassification. Individuals without recorded dates were considered unvaccinated; however, because this was the same for both case patients and controls it was unlikely to substantially affect VE or may bias toward a lower VE. Given the small sample size of cases analyzed, it was difficult to control for potential confounding factors and also reduced precision of the VE estimates.
The monovalent rotavirus vaccine was effective in preventing severe gastroenteritis caused by G9P [4] rotavirus, a strain fully heterotypic from the vaccine strain, indicating that the strain predominance in Mexico was unrelated to vaccine pressure. Because variations in rotavirus strain circulation can occur independently of vaccination, the role of vaccination in observed strain changes requires cautious interpretation. Our findings highlight the importance of continued rotavirus disease surveillance and the need to evaluate the performance of rotavirus vaccines as vaccination programs mature. 
